Zebeta

A cardioselective beta-1-adrenergic blocker. It is effective in the management of hypertension and angina pectoris. .
[PubChem].

Medicinal name:
  • Bisoprolol Fumarate 10 MG Oral Tablet [Zebeta]
  • Bisoprolol Fumarate 5 MG Oral Tablet [Zebeta]

Zebeta - Pharmacology:

Zebeta selectively blocks catecholamine stimulation of beta(1)-adrenergic receptors in the heart and vascular smooth muscle. This results in a reduction of heart rate, cardiac output, systolic and diastolic blood pressure, and possibly reflex orthostatic hypotension. Zebeta can also competitively block beta(2)-adrenergic responses in the bronchial and vascular smooth muscles, causing bronchospasm.

Zebeta mini report

Zebeta NDA
NDA - A product marketed under an approved New Drug Application
Zebeta TABLET, FILM COATED
TABLET, FILM COATED
Zebeta HUMAN PRESCRIPTION DRUG
HUMAN PRESCRIPTION DRUG
Zebeta global name
Bisoprolol Fumarate
Start - Stop data
START DATA:
1993-Oct-20
Start - Stop data
STOP DATA
2016-Oct-31

Zebeta for patients

Patients especially those with coronary artery disease should be warned about discontinuing use of ZEBETA without a physicians supervision. Patients should also be advised to consult a physician if any difficulty in breathing occurs, or if they develop signs or symptoms of congestive heart failure or excessive bradycardia.

Patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents should be cautioned that beta-blockers may mask some of the manifestations of hypoglycemia, particularly tachycardia, and bisoprolol fumarate should be used with caution. Patients should know how they react to this medicine before they operate automobiles and machinery or engage in other tasks requiring alertness.

Zebeta Interactions

ZEBETA should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that ZEBETA be discontinued for several days before the withdrawal of clonidine.

ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.

Concurrent use of rifampin increases the metabolic clearance of ZEBETA, resulting in a shortened elimination half-life of ZEBETA. However, initial dose modification is generally not necessary. Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics, digoxin, and cimetidine. There was no effect of ZEBETA on prothrombin time in patients on stable doses of warfarin.

Risk of Anaphylactic Reaction: While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reactions.

Zebeta Contraindications

ZEBETA is contraindicated in patients with cardiogenic shock, overt cardiac failure, second or third degree AV block, and marked sinus bradycardia.

Manufacturers name:

  • Duramed Pharmaceuticals, Inc

Generic name, Overdose, Half Life Zebeta, Food Interactions, Chemical, etc..

Zebeta see also FDA report Barrenwort

Brand Names containing Bisoprolol
Blood Pressure

Chemical structure:
O O O O N H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H C18H31NO4 2D chemical structure C18H31NO4 SVG | 2D structure chemical names, chemical properties, classification C18H31NO4